Latest news

• GSK announces positive phase 3 results of RSV vaccine candidate in older adults

  GSK has announced positive results from a phase 3 trial of its respiratory syncytial virus (RSV) vaccine candidate, RSVPreF3 OA, for adults aged 60 years and above. ... The phase 3 AReSVi-006 trial showed the vaccine candidate was highly efficacious,

• Sanofi and NIHR enrol first patient in immunisation study for RSV in infants

  Sanofi and the National Institute for Health and Care Research (NIHR) have announced that the first patient has been enrolled in the Hospitalised RSV Monoclonal Antibody Prevention – HARMONIE – trial. ... The European clinical trial will evaluate the

• Pfizer starts RSV trial ahead of winter season

  Earlier this year, AstraZeneca and Sanofi’s long-acting antibody nirsevimab met the primary endpoint in a late-stage respiratory syncytial virus (RSV) trial in healthy infants. ... Janssen also has a phase 3 trial looking at its vaccine candidate, Ad26

• AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

  AstraZeneca (AZ) and Sanofi’s long-acting antibody nirsevimab met the primary endpoint in a late-stage respiratory syncytial virus (RSV) trial in healthy infants. ... According to the companies, nirsevimab is the first potential immunisation to show

• GSK launches late-stage testing of RSV vaccine candidate in older adults

  GlaxoSmithKline (GSK) has launched a phase 3 trial investigating its respiratory syncytial virus (RSV) vaccine candidate in older adults. ... In a phase 1/2 trial of GSK’s RSV vaccine candidate in both young and older adults, the jab was found to have